Johnson & Johnson $2.2 Billion Settlement (2013)
The Johnson & Johnson (J&J) $2.2 billion settlement in 2013 stands as another major milestone in healthcare fraud enforcement—particularly in curbing deceptive pharmaceutical marketing. The case centered on allegations that J&J and its subsidiaries promoted several prescription drugs, including Risperdal and Invega, for off-label uses not approved by the FDA. The company was also accused […]
Johnson & Johnson $2.2 Billion Settlement (2013) Read More »